Tianci International Launches China's First Shared Pharmaceutical Manufacturing Platform in Shanghai to Build a Full-Chain Innovation Ecosystem

　　【China Pharmaceutical Network - Corporate News] On the 17th, a batch of major projects in Zhangjiang Science City were officially signed. Among them, Shanghai Tianci International Pharmaceutical Co., Ltd. separately entered into cooperation agreements with Fosun Kite Biotechnology Co., Ltd. and Shanghai Greenvalley Pharmaceutical Co., Ltd., under which two significant China-produced innovative drugs—Yescarta and Sodium Oligomannate Capsules (GV971)—will achieve industrialization in Zhangjiang Science City.
 

Fosun Kite’s new drug, Yescarta, is a CAR-T therapy and represents a leading international technology for the treatment of malignant tumors, with the potential to fill a gap in the Chinese market. Guanaratide Sodium Capsules (GV-971), jointly developed by Shanghai Greenvalley Pharmaceutical Co., Ltd., Ocean University of China, and the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, is the first new drug for Alzheimer’s disease to be launched globally in 16 years. It has completed Phase III clinical trials and applied for production approval, with mass production imminent. Going forward, both drugs will be manufactured on the Tianci International Shared Pharmaceutical Platform, which is about to become fully operational, and will be comprehensively launched on the market. Reportedly, shared pharmaceutical platforms have rarely been covered in the media prior to this.
 

Zhangjiang, hailed as “China’s Pharma Valley,” shoulders the national mission of new drug research and development (R&D). It has now become a landmark science and technology park characterized by highly concentrated R&D resources, rapid emergence of innovative achievements, and pioneering breakthroughs in new technologies and models. In recent years, Zhangjiang has seen a continuous stream of innovative drug achievements, with a cluster of new drugs being launched. Tang Shiqing, Director of the Science and Technology and Economic Commission of Pudong New Area, Shanghai, stated that after more than 20 years of development, Zhangjiang’s biopharmaceutical industry has entered a mature stage and gained global renown in the field of pharmaceutical R&D. However, for a long time, Zhangjiang has suffered from a persistent shortage of capabilities supporting manufacturing and production.
 

How will Zhangjiang ensure the production and implementation of original innovative drugs amid scarce production resources? How can “Zhangjiang R&D” be transformed into “Zhangjiang Intelligent Manufacturing”? How can the cost center of pharmaceutical R&D gradually evolve into a profit center for Chinese innovative enterprises? ... By adopting market-oriented innovation models and integrating R&D, production, and sales resources, a “flexible, open, and giving” shared pharmaceutical platform can be established, thereby addressing the “last mile” challenge in the industrialization of innovative drugs. This means that in the future, Shanghai will not only serve as the “source” of innovative drugs but also build a full-industry-chain ecosystem for innovative pharmaceuticals.
 

It is understood that new drugs must undergo stages including drug discovery, preclinical research, clinical trials, manufacturing, and commercialization. Traditional pharmaceutical manufacturers are highly closed-off, often producing only their own proprietary drugs, and lack social service orientation and creativity. In contrast, shared pharmaceutical platforms have created a novel biopharmaceutical ecosystem, encompassing drug manufacturing services, clinical research services, drug sales services, drug registration services, and financial services, thereby addressing the most significant pain points in the current biopharmaceutical industry.
 

Guided by the national Marketing Authorization Holder (MAH) policy, Tianci International has basically completed the construction of its shared pharmaceutical manufacturing platform, the “Sci-Tech Innovation Dream Factory,” which is poised to commence operations. Covering an area of 211 mu with a gross floor area of 280,000 square meters, the facility comprises 20 standard workshop buildings and can accommodate up to 80 Good Manufacturing Practice (GMP)-compliant production lines.
 

Tang Shiqing believes that the innovative development of the Tianci Shared Pharmaceutical Platform embodies Zhangjiang’s vision and reforms for the next round of upgrading in the biopharmaceutical industry. The platform’s pioneering efforts facilitate Zhangjiang’s pharmaceutical sector in transitioning from the innovation chain to the value chain, playing a decisive role in enabling positive cash flow for innovative enterprises and supporting their subsequent R&D upgrades. Furthermore, the shared pharmaceutical platform helps establish a true closed-loop ecosystem for Zhangjiang’s biopharmaceutical industry, potentially ushering in a new era of pharmaceutical manufacturing.
 

Tang Shiqing revealed that government departments will prioritize support for this innovative platform, comprehensively enhance governmental service standards, and promote the development of professional capabilities across the industry, thereby enabling new drugs “Made in Shanghai” to reach global markets.